Travere Therapeutics (TVTX) Debt Ratio (2014 - 2025)

Travere Therapeutics (TVTX) posted Debt Ratio of 0.12 for Q2 2025, down 1.06% on a QoQ basis from 0.13 in Q1 2025.

Travere Therapeutics (TVTX) Debt Ratio (2014 - 2025) Analysis & Trends

Travere Therapeutics' Debt Ratio history runs 10 years deep, the most recent figure standing at 0.12 for Q2 2025.

Quarterly Debt Ratio changed N/A year-over-year to 0.12 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 0.12 (changed N/A YoY) and the FY2024 annual result came in at 0.12, changed N/A from the prior year.
Debt Ratio was 0.12 for Q2 2025 at Travere Therapeutics, down from 0.13 in the prior quarter.
Across five years, Debt Ratio topped out at 0.14 in Q3 2024 and bottomed at 0.01 in Q1 2023.
A 5-year average of 0.05 and a median of 0.01 in 2022 frame the typical range for Debt Ratio.
Annual changes were most pronounced in 2021 — Debt Ratio tumbled 66.74% — and 2022, when it increased 9.23%.
Travere Therapeutics' Debt Ratio stood at 0.01 in 2021, then climbed by 9.23% to 0.01 in 2022, then retreated by 9.97% to 0.01 in 2023, then surged by 1133.73% to 0.12 in 2024, then increased by 7.24% to 0.12 in 2025.
Business Quant data shows TVTX's Debt Ratio at 0.12 in Q2 2025, 0.13 in Q1 2025, and 0.12 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Travere Therapeutics	5.21 Bn	5.21 Bn	125.25 Mn	-

Download Data